BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211118
DTEND;VALUE=DATE:20211219
DTSTAMP:20260515T231522
CREATED:20211018T092817Z
LAST-MODIFIED:20211018T092817Z
UID:31844-1637193600-1639871999@www.pharmajournalist.com
SUMMARY:CPhI & P-MEC China Virtual Expo Connect 2021
DESCRIPTION:Virtual Expo Connect” is the digital extension of the physical CPhI & P-MEC China event that offers an online alternative for global pharma professionals. Powered by PharmaSources.com\, Virtual Expo Connect builds an online platform to be accessed from anywhere\, adding valued services and infinite opportunities to connect\, learn\, trade and grow. \nTo know more visit: https://bit.ly/3ASODPZ
URL:https://www.pharmajournalist.com/event/cphi-p-mec-china-virtual-expo-connect-2021/
LOCATION:Online
ORGANIZER;CN="Informa Markets":MAILTO:Candice.lau@informa.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211206
DTEND;VALUE=DATE:20211210
DTSTAMP:20260515T231522
CREATED:20210817T215306Z
LAST-MODIFIED:20210817T215306Z
UID:31360-1638748800-1639094399@www.pharmajournalist.com
SUMMARY:3rd Gene Therapy for Neurological Disorders
DESCRIPTION:Returning to Boston this December\, the 3rd Gene Therapy for Neurological Disorders meeting will welcome discovery\, preclinical\, translational and clinical industry scientists to share\, learn and network for the shared goal of successfully and safely delivering gene therapies to the CNS. \nWith 40+ expert leaders from the likes of Taysha Gene Therapies\, Passage Bio\, AskBio\, Neurogene\, Affinia Therapeutics and Alcyone Therapeutics sharing their progress\, don’t miss the chance to join the industry’s definitive physical conference to make new connections and reconnect with your friends and colleagues. \nOver 4 comprehensive days of networking\, presentations and discussion sessions\, this meeting will enable you to: \n\nDiscuss the latest DRG toxicity and immunogenicity research to understand the biology behind AAV toxicity in the CNS\nEvaluate current safety and toxicity strategies to navigate off target effects including redosing options\nEvaluate intraparenchymal\, intra-cisterna magna\, lumbar intrathecal and systemic delivery routes for CNS indications to assess CNS tropism and biodistribution\nHear from neurosurgeons at the forefront of delivery and explore the most up to date delivery devices to identify novel innovations and areas for development\nReview pharmacological concepts for preclinical dose selection in NHP biodistribution case studies to optimize dose extrapolation\nLearn about the different vector discovery strategies used to identify vectors with improved CNS tropism and specificity\nOptimize clinical trial design considerations for both paediatric and adult neurological patient populations to showcase efficacy to regulators and deliver value for patients\nDiscover the novel indications being targeted by gene therapies such as epilepsy\, neuropathic pain and hearing disorders to improve your knowledge of current CNS pipelines\n\nView your copy of the event guide now: https://ter.li/yrofx9
URL:https://www.pharmajournalist.com/event/3rd-gene-therapy-for-neurological-disorders/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211207
DTEND;VALUE=DATE:20211210
DTSTAMP:20260515T231522
CREATED:20210812T114045Z
LAST-MODIFIED:20210812T114045Z
UID:31282-1638835200-1639094399@www.pharmajournalist.com
SUMMARY:iPSC-Derived Cell Therapies Summit
DESCRIPTION:Capitalize on the Scalable & Diverse Potential of iPSC-Derived Therapies By Defining Differentiation Protocols\, Optimal Cell Line Selection & Optimizing Gene Engineering To Accelerate Successfully Into the Clinic \nThe explosion of excitement and investment in the iPSC field has ushered in a new era of cell therapy\, with these cells establishing its place as the optimal starting material for cell therapies targeting cancer\, autoimmune\, cardiac disease and much more. \nThe iPSC-Derived Cell Therapies Summit is your dedicated forum exclusively focused on the common challenges across disease indications which are limiting the clinical translation of iPSC-based approaches for cell therapy\, including safety concerns with differentiation protocols\, lack of regulatory guidance\, and licensing issues. \nGet caught up to speed on this dynamic industry with expertise shared from the likes of Shoreline Biosciences\, Kite Pharma\, HeartSeed\, and Exacis\, to understand the broad applicability of iPSCs\, advances in novel gene engineering approaches\, and translational lessons learned to advance your pipeline to clinical success. \nLeave this meeting with the knowledge and connections to landscape the clinical progression\, outline GMP compliant processes for scale up\, and share strategies to ensure consistency in starting material. \nThis is your opportunity to collaborate with 80+ iPSC senior level experts from biopharma and academia and be at the forefront of the future of cell therapy by joining the mission to develop safe\, scalable and cost-effective iPSC-derived therapies. \nTo Know more visit: https://ter.li/e7gdu7
URL:https://www.pharmajournalist.com/event/ipsc-derived-cell-therapies-summit/
LOCATION:Virtual/Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211207
DTEND;VALUE=DATE:20211210
DTSTAMP:20260515T231522
CREATED:20210819T081104Z
LAST-MODIFIED:20210819T081104Z
UID:31364-1638835200-1639094399@www.pharmajournalist.com
SUMMARY:Synthetic Biology-Based Therapeutics Summit
DESCRIPTION:Engineer ‘Intelligent’\, Controllable Drugs at the First Technical Meeting Dedicated to Advancing the Therapeutic Applications of Synthetic Biology \nThis year\, the synthetic biology market has seen fledgling companies rise to IPO smashing power players\, as the demand for high-quality\, engineered biomolecules and controllable therapeutics grows exponentially. \nThe therapeutic potential of novel synthetic units is huge\, but challenges remain in demonstrating proof-of-concept\, developing assays\, functional characterization\, manufacturing scale-up\, and identifying therapeutic applications for commercial development. \nWith an agenda curated by leaders in synthetic biology-based therapies at Synlogic\, Merck\, Bayer\, Senti Bio\, MIT and GSK\, the Synthetic Biology-Based Therapeutics Summit will provide strategic insights to deploy synthetic biology as a tool for discovery\, through to therapeutic applications. \nExplore innovations in circuit design and implementation\, harnessing the power of computation and AI to better design functioning circuits and uncover novel components which elicit therapeutic benefit. Tackle manufacturing challenges to scale up synthetic biology-based therapeutics with gold-standard quality control and characterization. \nTo Know more visit: https://ter.li/19 mj8t
URL:https://www.pharmajournalist.com/event/synthetic-biology-based-therapeutics-summit/
LOCATION:Digital | EST
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211207
DTEND;VALUE=DATE:20211210
DTSTAMP:20260515T231522
CREATED:20210823T104601Z
LAST-MODIFIED:20210823T104827Z
UID:31394-1638835200-1639094399@www.pharmajournalist.com
SUMMARY:3rd Annual Targeted Radiopharmaceuticals (TRP) Summit 
DESCRIPTION:The 3rd Targeted Radiopharmaceuticals (TRP) Summit returns at a crucial time for the entire industry. Spurred on by positive Phase III VISION trial data\, there has been huge research investment\, on both sides of the Atlantic\, on how to deliver radiation therapy directly and specifically to tumours. \nFor the 2021 edition of this conference\, there will be the opportunity to attend either in-person in Berlin or remotely via a dedicated digital networking platform with all the access to the conference content. \nYou can expect a wider array of insights from recent case studies to help you accelerate the development of the next generation of radioligand therapies from clinical approval to commercialisation. \nAs the only industry-led platform for discussing challenges and opportunities facing developers of theranostic radioligand therapies\, we strive to tackle topics that are on every drug developer’s mind: \n\nHow do we identify and validate new targets?\nCan we combine Targeted Radiopharmaceuticals with immunotherapy or other targeted oncology methods?\nHow do we improve current clinical design methodologies and patient selection strategies?\nWhere can improvements be made to the current supply and fulfilment models?\n\nTo know more visit: https://ter.li/r1oll2
URL:https://www.pharmajournalist.com/event/3rd-annual-targeted-radiopharmaceuticals/
LOCATION:Berlin Germany\, & Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211207
DTEND;VALUE=DATE:20211210
DTSTAMP:20260515T231522
CREATED:20210826T090709Z
LAST-MODIFIED:20210826T090829Z
UID:31471-1638835200-1639094399@www.pharmajournalist.com
SUMMARY:4th Commercializing Clinically Validated Digital Therapeutics Summit
DESCRIPTION:The 4th Commercializing Clinically Validated Digital Therapeutics Summit returns in December of 2021 as the only industry-led meeting deep-diving on stakeholder alliance and partnership to accelerate DTx scalability\, to enable building sustainable & viable business models. \nDTx is happening\, and happening fast on a global scale. The amount of investment continues to surge\, and is expected to reach $15\,176m in 2027. Following the pandemic\, with more emphasis on digital medicine\, telemedicine\, and decentralized clinical trials\, DTx adoption has peaked. Now is the time to join with key stakeholders across regulatory\, pricing\, physician engagement\, real world evidence\, commercial functions\, patient adherence and adoption to combat the challenges and ensure delivery of cutting edge DTx to your patients. \n \nFurthermore\, the pandemic has been the major catalyst to DTx adoption with tremendous benefits brought to patients\, physicians for treatment\, and remote clinical trials that made 2021 an inflection point for the DTx industry. \nAcross 3 days covering extensive and valuable content\, we will bring together expert speakers to share their data on case studies of lessons learnt and keys to success\, as well as insights into venturing into effective partnerships. This will give you the tools to conquer your most crucial challenges and accelerate sustainable scalability and adoption of your digital therapeutic. \nWhether you are a drug\, med device or a DTx developer\, this is your must-attend event in 2021. Hear from your peers’ journeys and lessons learned\, and re-engage in the long awaited dialogue to generate clinical and RWE\, in order to serve our patients in need beyond just a pill! \nTo know more visit: https://ter.li/cyw0ze
URL:https://www.pharmajournalist.com/event/4th-commercializing-clinically-validated-digital-therapeutics-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211207
DTEND;VALUE=DATE:20211210
DTSTAMP:20260515T231522
CREATED:20210903T051629Z
LAST-MODIFIED:20210903T133327Z
UID:31553-1638835200-1639094399@www.pharmajournalist.com
SUMMARY:4th RNA-Targeted Drug Discovery Summit
DESCRIPTION:The 4th RNA-Targeted Drug Discovery Summit is returning once again this December\, to reunite the largest community of thought leaders and experts in biology\, chemistry and RNA therapeutics to discuss cutting-edge small molecule strategies capable of interacting with and modulating RNA with improved specificity\, selectivity and drug-like properties. \nJoin the leading RNA small molecule forum alongside 150+ biopharmaceutical Directors\, VPs and C-Level Executives to hear the latest pioneering case studies and successfully translate your discovery and pre-clinical strategies into robust pipelines of RNA-targeted small molecule drugs that realize the full potential of this up-and-coming field. \nWe’re back in 2021 with a more comprehensive program than ever before & we’d love you to join us! \nKey Highlights: \n\nExpand your knowledge of the RNA landscape by gaining exclusive insights and data-driven updates to streamline the success of your RNA candidates from leaders of the field such as Nymirum\, Arrakis\, PTC Bio& Expansion Therapeutics\n\n\nOptimize and advance your RNA structural insights to guide the successful discovery & development of your RNA targeted small molecule with insights from Novartis\, AstraZeneca\, Stanford University &National Cancer Institute\n\n\nEvaluate tested & novel structure-based methods for understanding RNA-ligand interactions and binding sites alongside academic leaders Hashim Al-Hashimi\, Matthew Disney\,Amanda Garner\, Aaron Frank & Anthony Mustoe\n\n\nOvercome selectivity\, specificity & toxicity challenges and accelerate the translation of your RNA small molecule pipeline into clinical development with discussions from\nAnima Biotech\, MD Anderson Cancer Center & AstraZeneca\n\n\nDiscovery of novel chemical matter & new chemical space for small molecule intervention with insights from Roche\, University of Michigan\, Baylor College Medicine\, Remix Therapeutics\, Ladder Therapeutics &Biosplice Therapeutics\n\nTo know more visit: https://bit.ly/3mWyANC
URL:https://www.pharmajournalist.com/event/4th-rna-targeted-drug-discovery-summit/
LOCATION:Digital Event\, EST
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211207
DTEND;VALUE=DATE:20211210
DTSTAMP:20260515T231522
CREATED:20210917T065655Z
LAST-MODIFIED:20210917T065655Z
UID:31690-1638835200-1639094399@www.pharmajournalist.com
SUMMARY:TIGIT Therapies Summit
DESCRIPTION:TIGIT therapies have seen promising clinical validation\, spearheading the next wave of Immune Checkpoint Inhibitors. As such there has been an explosion of interest and high-scale investment into this exciting space. \nArriving at a critical point for TIGIT development\, the 2nd Annual TIGIT Therapies Summit is the definitive industry-led event focused at propelling this next generation inhibitor to clinical use. \nEnsure your TIGIT program reaches full clinical potential through hearing from experts about optimizing the mechanism of action\, refining Fc receptor co-engagement\, devising effective drug design\, rationalizing checkpoint combinations and utilizing biomarkers to harness the therapeutic potential of the TIGIT and DNAM-1/CD226 axes. \nJoin leaders in TIGIT development from GSK\, Gilead Sciences\, Arcus\, iTeos\, Compugen\, BeiGene\, Seattle Genetics\, Mereo BioPharma\, Harvard\, Stanford and more! \nThis event will allow you to address the key challenges associated with TIGIT therapy development and propel TIGIT to clinical use. Download the event guide to see how you can get involved.
URL:https://www.pharmajournalist.com/event/tigit-therapies-summit/
LOCATION:Digital
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR